Title of the cohort

The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study

Acronym for cohort

ATBC Study

Name of Principal Investigator
TitleResearch professor, MD, Ph.D
First nameJarmo
Last nameVirtamo
Address of institution where award is held
InstitutionThe National Institute for Health and Welfare
Street AddressMannerheimintie 166
  • Finland


Contact email
Funding source
1. The cohort includes, or expects to include, incidence of the following conditions
  • Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible
  • Already possible
2a. Stated aim of the cohort

ATBC Study was a randomized, double-blind, placebo-controlled, primary prevention trial to determine whether daily supplementation with alpha-tocopherol, beta-carotene, or both would reduce the incidence of lung or other cancers among male smokers.

2b. Features distinguishing this cohort from other population cohorts
3a. i) Number of publications that involve use of cohort to date


3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)


4a. Study criteria: age range of participants at recruitment
Age in years from:50
To (‘until death’ if applicable):69
4b. Study criteria: inclusion criteria

Men of 50-69 years old smoking 5 or more cigarettes a day

4c. Study criteria: exclusion criteria

Men who had prior cancer or serious illness or who reported current use of vitamins E (>20 mg/day), A (>20,000 IU/day), or beta-carotene (>6 mg/day) were ineligible.

5. Size of the cohort (i.e. number of participants enrolled)
  • More than 15,000
6a. Measures used to characterise participants


6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
  • No
7. Study design
  • Longitudinal
8. Cases matched by
  • Other health assessment (specify) / N/A
  • no neurodegenerative case-control definition
9a. Does the study include a specialised subset of control participants
  • No
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date


10a. ii) Data collection end date


10a iii) Data collection for this study is
  • Data analysis ongoing
  • Closed to new patients
10b. Plans to continue the cohort study beyond the current projected end date
  • No
11. Data collected
  • Through links to other records or registers (such as dental records, police records etc). Please specify
  • Finnish cancer registry, morbidity registry
12. System in place to enable re-contact with patients for future studies
13a. Format and availability of data stored in a database
Language used:
13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups


14b. Access policy/mechanisms for access if data are available to other groups
  • Apply to PI or co-ordinator at resource
  • Access Committee mechanism
  • National access
  • International access
  • Resource has own ethics approval so usually no need for separate external ethics approval
15. Data sharing policy specified as a condition of use
  • Data made publicly available after a specified time point
16a. Are tissues/samples/DNA available to other groups


16b. i) Description of available tissues/samples/DNA
  • Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data


17. Is information on biological characteristics available to other groups
  • No

    Types: Population Cohorts
    Member States: Finland
    Diseases: Neurodegenerative disease in general
    Years: 2011
    Database Categories: N/A
    Database Tags: N/A

    Export as PDF